Exchange: NASDAQ·Updated 04:53 PM EDT
News
all
press releases
New Publication Establishes Strong Clinical Validation of Signatera for MRD Assessment in Lymphoma
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in Blood Neoplasia, validating the prognostic and predictive value of Signatera in patients with both newly diagnosed and relapsed/refractory (R/R) lymphoma. PET/CT...
Business Wire
More News
Billionaire Stanley Druckenmiller Has Roughly 17% of His $5.2 Billion Duquesne Portfolio in Natera Stock. Is It Still a Buy After an 80% Run?
Key PointsNatera ranks as the top holding in Druckenmiller's Duquesne Family Office portfolio...
Nasdaq News: Markets
Natera & Angiex Partner to Evaluate AGX101 Response With Signatera
NTRA teams with Angiex to use Signatera in a Phase 1 AGX101 trial, aiming to track ctDNA and deepen insights into treatment response.
Zacks
Natera and Susan G. Komen Announce National Partnership to Accelerate Progress Against Breast Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a national partnership with Susan G. Komen, the worlds leading breast cancer organization. Together, the organizations aim to accelerate breast cancer awareness and education, including...
Business Wire
Natera Partners With Angiex For CtDNA Monitoring In Solid Tumor Trial Using Signatera
(RTTNews) - Natera, Inc. (NTRA), a clinical genetic testing company announced on Thursday that it will collaborate with privately held Angiex, Inc., to use its Signatera test for circulating tumor DNA monitoring in a Phase I study of AGX101, an investigational nuclear-delivered a...
Nasdaq News: Markets
Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate Using Signatera
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new Signatera collaboration with Angiex, Inc., a privately held biotech company developing a portfolio of Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs). Angiex is conducting a Phase I...
Business Wire
Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Reveal
Key PointsThe fund's top holding is cell-testing company Natera...
Nasdaq News: Markets
VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity?
Veracyte's 25.3% sell-off improves the entry price as strong core test demand and earnings growth face valuation, reimbursement and launch risks.
Zacks
Interesting NTRA Put And Call Options For August 2027
Investors in Natera Inc (Symbol: NTRA) saw new options become available today, for the August 2027 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 361 days until expiration the newly available contracts re...
Nasdaq News: Markets
Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.
Key PointsDruckenmiller's Natera bet signals strong conviction in the future of personalized, blood-based diagnostics...
Nasdaq News: Markets

Advertisement|Remove ads.